Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Brno – page 28

394 clinical trials in Brno, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Brno at a glance
394
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

394 trials in Brno

Open in trial search

Chronic lymphocytic leukaemia

Not recruiting

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Escherichia urinary tract infection

Not recruiting

Study of ExPEC9V vaccine for preventing invasive E.

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ECOO15
  • Sponsor:Janssen Vaccines & Prevention B.V.

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Clear cell papillary renal cell carcinoma

Not recruiting

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Eosinophilic oesophagitis

Not recruiting

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study of Durvalumab and Tremelimumab for Patients with Limited Stage Small-Cell Lung Cancer After Chemoradiation Therapy

Not recruiting
Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dextrose Bp
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Cardiac failure chronic

Not recruiting

Study on the Effects of AZD5462 for Patients with Stable Chronic Heart Failure

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:AZD5462
  • Sponsor:AstraZeneca AB

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Brno

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for leukemia, prostate cancer, and gastric cancer.

  • Chronic Lymphocytic Leukemia
  • Metastatic Prostate Cancer
  • Esophageal Cancer
  • Advanced Breast Cancer

Studies evaluating novel therapeutic combinations and targeted treatments for various cancer types.

02 Autoimmune Conditions

Research focused on treating inflammatory disorders and autoimmune conditions, with particular emphasis on innovative therapies.

  • Ulcerative Colitis
  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Multiple Sclerosis

Evaluating new biological treatments and their long-term effectiveness in managing chronic conditions.

03 Respiratory and Cardiovascular

Studies addressing respiratory diseases and heart conditions, focusing on prevention and treatment strategies.

  • Chronic Obstructive Pulmonary Disease
  • RSV Prevention
  • Heart Failure Prevention
  • Cardiovascular Risk Management

Testing innovative approaches to improve patient outcomes in respiratory and cardiac conditions.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.